Fox Jennifer Lynne reported grant involving 139,267 derivative units of MYRIAD GENETICS INC at $0.00 for $0 on Nov 6, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Legal & Corp Strategy
Chief Legal & Corp Strategy
Filed Nov 9, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
139,267Time-Based Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
139,267Direct
Trade date
Nov 6, 2026Grant
Filed
Nov 9, 2026, 4:13 PM ET3-day reporting delay
Accession
0001914879-26-000008Code A · Transaction 395869
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MYGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MYGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −25%1w ago +9.6%1d ago +9.6%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents a one-time non-qualified stock option granted as a retention award under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement. F2: The exercise price equals the closing price of the Issuer's common stock on November 6, 2026, the grant date.